Gastroparesis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Gastroparesis – Drugs In Development, 2024 report and make more profitable business decisions.
Gastroparesis, also called delayed gastric emptying, is a disorder that slows or stops the movement of food from stomach to small intestine, even though there is no blockage in the stomach or intestines. The symptoms of gastroparesis may include feeling full shortly after starting a meal, feeling full long after eating a meal, nausea, and vomiting. Diabetes is the most common known cause of gastroparesis.
The Gastroparesis drugs in development market research report provide comprehensive information on the therapeutics under development for Gastroparesis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastroparesis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Gastroparesis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 16 molecules, with 16 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Gastroparesis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Gastroparesis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Gastroparesis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Cellix Bio Pvt LtdCinRx Pharma LLC
First Wave BioPharma Inc
Johnson & Johnson
Mebias Discovery LLC
Neurocrine Biosciences Inc
Neurogastrx Inc
Processa Pharmaceuticals Inc
PTC Therapeutics Inc
RaQualia Pharma Inc
Renexxion LLC
RosVivo Therapeutics Inc
Suzhou Regend Therapeutics Co Ltd
Vanda Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Gastroparesis reports